Labcorp EVP van der Vaart sells $1.06m in shares

Published 15/08/2025, 16:00
Labcorp EVP van der Vaart sells $1.06m in shares

{{8113|{{8113|{{8113|Labcorp}} Holdings Inc.}}}} NASDAQ:LH Executive Vice President and Chief Legal Officer Sandra D. van der Vaart sold 3,903 shares of common stock on August 13, 2025, for a total of $1.06 million. The shares were sold at a price of $271.4249, close to the stock’s 52-week high of $283.47. The $22.5 billion healthcare services provider has seen its shares rise nearly 19% year-to-date. InvestingPro data shows the stock typically trades with low volatility, making this insider transaction particularly noteworthy.

On the same day, van der Vaart also exercised options to acquire 3,903 shares of Labcorp common stock at a price of $131.43, for a total value of $512971. These options were related to non-qualified stock options and fully vested as of February 12, 2020.

Following these transactions, van der Vaart directly owns 2,273.6691 shares of Labcorp Holdings Inc. It includes 30.1294 shares acquired on June 30, 2025 under the Labcorp Holdings Inc. Amended and Restated 2016 Employee Stock Purchase Plan.

In other recent news, Laboratory Corporation of America reported strong financial results for the second quarter of 2025, surpassing analysts’ expectations. The company achieved an adjusted earnings per share (EPS) of $4.35, exceeding the forecasted $4.17. Additionally, Labcorp recorded revenues of $3.53 billion, outperforming the anticipated $3.48 billion. Following these results, Jefferies raised its price target for Labcorp to $300, maintaining a Buy rating, citing a 1% top-line beat and a 6% upside in its Base Business segment. Evercore ISI also increased its price target to $300, highlighting strong diagnostic growth from both organic sources and acquisitions. Leerink Partners set an even higher price target of $323, praising the company’s performance in its diagnostics business and biopharma laboratory services division. These developments reflect a positive outlook from multiple analyst firms on Labcorp’s recent performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.